- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04781712
Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer (MMHTR)
October 25, 2022 updated by: JiHye Hwang, Samsung Medical Center
Feasibility of a Modular mHealth for Tailored Rehabilitation During the Treatment of Breast Cancer
This study investigated the feasibility of the novel modular mobile health (mHealth) for personalized rehabilitation and explored the participants' satisfaction and app data during treatment of breast cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is prospective, feasible, parallel study in post-operative patients with breast cancer and during treatment.
Disability of Arm, Shoulder, Hands (DASH), Physical activity data (IPAQ-SF), Physical measurement such as hand grip strength, body mass index (BMI), muscle mass, and differences in arm circumference, PRO-CTCAE, Distress Thermometer, needs and satisfaction in app, personal health record of app (exercise, daily step count, etc.) Measure will be evaluated on 1-month, 2-month, 4-month, 6-month, 9-month, and 12-month after POD.
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Korea, Republic of, 06351
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Unilateral breast cancer at TNM stage 0 ~ III
- Patients who will undergo the treatment (chemotherapy, radiation therapy, and hormone therapy) after surgery
- Patients who had a mobile phone (Android or iOS)
Exclusion Criteria:
- Patients who have metastases or recurrence to other organs were excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Self-management using mHealth
Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
|
an individually tailored self-management through the mHealth app with a smart band worn on the wrist
Other Names:
|
|
NO_INTERVENTION: Exercise using brochure
Only exercise using brochure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
satisfaction score in app contents
Time Frame: 1 to 12month
|
satisfaction score in app contents, Likert scale (5-point, higher scores mean a better)
|
1 to 12month
|
|
Needs score in app contents
Time Frame: 1 to 12month
|
Needs score in app contents, Likert scale (5-point, higher scores mean a better)
|
1 to 12month
|
|
DASH (Disabilities of Arm, Shoulder, Hands)
Time Frame: 1 month, 2month, 4month, 6month, 9month, 12month
|
Change from Baseline DASH score at 12 months, higher scores mean a worse (0-100)
|
1 month, 2month, 4month, 6month, 9month, 12month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical measurement (handgrip strength)
Time Frame: 1 to 12month
|
Handgrip strength (kg)
|
1 to 12month
|
|
Physical measurement (of body composition, BMI)
Time Frame: 1 to 12month
|
Body mass index
|
1 to 12month
|
|
Physical measurement (of body composition, muscle mass)
Time Frame: 1 to 12month
|
muscle mass
|
1 to 12month
|
|
Physical measurement (upper extremity volume)
Time Frame: 1 to 12month
|
differences in arm circumference
|
1 to 12month
|
|
Physical activity (IPAQ-SF Questionnaire)
Time Frame: 1 to 12month
|
Total METs within recent 7 days (vigorous, moderate, walking, sitting), higher values mean a better
|
1 to 12month
|
|
PRO-CTCAE (patients reported outcomes)
Time Frame: 1 to 12month
|
Symptoms during treatment
|
1 to 12month
|
|
Distress thermometer (distress level)
Time Frame: 1 to 12month
|
Distress level during treatment, higher scores mean a worse (0-10)
|
1 to 12month
|
|
App use data (personal health record)_Exercise compliance rate
Time Frame: 1 to 12month
|
Exercise time, higher values mean a better
|
1 to 12month
|
|
App use data (personal health record)_Physical activity change
Time Frame: 1 to 12month
|
daily step count (number), higher values mean a better physical activity
|
1 to 12month
|
|
App use data (personal health record)_interest of contents
Time Frame: 1 to 12month
|
contents view (number), higher values mean a better compliance rate
|
1 to 12month
|
|
App use data (personal health record)_sleep
Time Frame: 1 to 12month
|
sleep compliance rate (%), higher values mean a better compliance rate
|
1 to 12month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 22, 2019
Primary Completion (ACTUAL)
March 30, 2021
Study Completion (ACTUAL)
March 30, 2021
Study Registration Dates
First Submitted
February 22, 2021
First Submitted That Met QC Criteria
March 1, 2021
First Posted (ACTUAL)
March 4, 2021
Study Record Updates
Last Update Posted (ACTUAL)
October 26, 2022
Last Update Submitted That Met QC Criteria
October 25, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMC-2018-10-062
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
Clinical Trials on Modular mHealth for Tailored Rehabilitation
-
Turku University HospitalActive, not recruitingFatigue Syndrome, Chronic | Functional Disorder | Persistent Physical Symptoms (PPS)Finland
-
Helsinki University Central HospitalRecruitingPost Covid-19 ConditionFinland
-
Boston University Charles River CampusNational Institute of Mental Health (NIMH)CompletedDepressive Disorder | Anxiety DisordersUnited States
-
Makerere UniversityCompletedHuman Immunodeficiency VirusUganda
-
Gazi UniversityCompletedHemiplegia | Anosognosia | Right Hemispheric Stroke | Hemispatial NeglectTurkey
-
Rigshospitalet, DenmarkCopenhagen University Hospital, DenmarkRecruitingHeart Arrest | Rehabilitation | Cardiac Arrest | Cardiac Rehabilitation | Cardiopulmonary Resuscitation | Recovery of Function | Return to Work | Return-to-workDenmark
-
University of California, San FranciscoThis work was made possible by residual class settlement funds in the matter...Recruiting
-
Makerere UniversityInfectious Diseases Institute, UgandaCompletedmHealth | HIV-1-infection | ART AdherenceUganda
-
Medical Research Council Cognition and Brain Sciences...Cambridgeshire and Peterborough NHS Foundation TrustCompletedObsessive-Compulsive Disorder | Generalized Anxiety Disorder | Major Depressive Disorder | Posttraumatic Stress Disorder | Social Anxiety Disorder | Panic Disorder | Agoraphobia | Illness Anxiety DisorderUnited Kingdom
-
Harvard UniversityAnnie E. Casey Foundation; MacArthur Foundation; Casey Family ProgramsCompletedDepression | Problem Behavior | Anxiety | TraumaUnited States